- $3.50bn
- $4.39bn
- $1.86bn
Brief: Ashland Announces Appointment Of Two New Directors As Part Of Cooperation Agreement With Stockholder Ancora
Ashland Q3 profit beats on higher volume, pricing; cuts FY EPS forecast
Brief: Ashland Q3 EPS USD 0.35
Brief: Chemical-Maker Ashland Is Said To Near Settlement With Ancora - Bloomberg News
Activist investors make bigger push for campaigns in H1, seek more M&A
U.S. RESEARCH ROUNDUP-Apogee Therapeutics, GE Healthcare, Synopsys
Brief: Chemicals Maker Ashland Pushed To Sell By Activist Cruiser - Bloomberg News
Brief: Ashland Responds To Investor Presentation By Ancora Alternatives Llc
Deals of the day-Mergers and acquisitions
Activist Ancora builds stake in Ashland, pushes for sale
Activist Ancora builds stake in Ashland, pushes for sale
Brief: Ashland - Enters Second Amended And Restated Credit Agreement On May 28, 2026 - SEC Filing
U.S. RESEARCH ROUNDUP-IBM, Lumentum Holdings, TransDigm Group
U.S. RESEARCH ROUNDUP-Alphabet, Amazon, Meta
Specialty chemicals maker Ashland cuts 2026 sales outlook
Brief: Ashland Inc Updated Outlook Includes About $11M In Temporary Impacts From Calvert City Startup Delay,Recent Weather Disruptions, All Isolated To Q2
Brief: Ashland Reports First Quarter Fiscal 2026 Results And Narrows Full-Year Outlook
Ashland Q1 revenue misses expectations, hurt by Avoca divestiture
Ashland misses Q4 revenue estimates